IP’s “PR problem” will be Discussed by Leading Figures at Public Event in New York

What to do about intellectual property’s negative image is the focus of the IP Awareness Summit, a gathering of concerned owners, educators and creators, Nov 29

Remarkably, in what I believe amounts to Orwellian ‘doublespeak,’ those who’ve been advancing the patent troll narrative argue that they do so because they are actually pro-innovation.”

— USPTO Director Andrei Iancu

NEW YORK, NY, USA, November 13, 2018 /EINPresswire.com/ — Leading intellectual property owners, creators, educators organizations and managers will consider the best ways to improve literacy about the role and impact of IP rights at the second annual IP Awareness Summit in New York on November 29.

IPAS will examine how increases in information access and speed have affected how patents, copyrights, trademarks, and trade secrets are seen and why they often fail to be accepted as “legitimate” property. The Summit also will address improving IP literacy through education and the media. Registration is open to the public.

IP Thought-Leaders

Featured speakers include United Stated Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO), Director Andrei Iancu, leading inventors, educators and the media.

Director Iancu said in fireside chat before more than 600 members of the Licensing Executives Society in Boston on October 15 that IP faces a public relations problem and the once heralded American inventor is no longer seen as a hero. He amplified those remarks at a speech later that week before the Eastern District of Texas Bar Association:

“Remarkably, in what I believe amounts to Orwellian ‘doublespeak,’ those who’ve been advancing the patent troll narrative argue that they do so because they are actually pro-innovation. That by their highlighting, relentlessly, the dangers in the patent system, they actually encourage innovation…

“What an odd message to deliver in the 21st century. What an odd message to deliver in America in particular, a country of risk-takers, entrepreneurs and inventors. An odd message indeed, especially given the incredible success of the American patent system over time.”

Others who will address be addressing IP literacy issues at IPAS 2018 include Manny Schecter, Chief Patent Counsel at IBM and President of the Intellectual Property Owners Education Foundation, and Jay walker, entrepreneur, Priceline.com founder, TEDMED curator and one of the most prolific U.S. inventors. There will be panels, other speakers and breakouts with audience participation.

Among those already registered for IPAS 2018 are IP owners, executives, educators, creators, service providers, investors, lawyers, IP organizations and the media. The remaining tickets will go fast.

To see all of the presenters and the program, go here.

To register, use this link.

About the Center for IP Understanding

The Center for Intellectual Property Understanding is an independent, non-profit organization dedicated to increasing awareness of IP rights and their impact on people’s lives. CIPU provides information, conducts research and facilitates activities that seek to make IP more intelligible, enhance value and deter theft. The Center also tracks attitudes toward IP rights, including patents, copyrights, and trademarks, and through outreach, provides an education framework for understanding how IP promotes competition and creates jobs. To learn more, please visit www.understandingip.org.

Bruce Berman
Center for IP Understanding
+1 212-508-9664
email us here


Source: EIN Presswire

Changing 3 Words of Dread to Optimism

3D illustration of Lungs

Wesley Baker - CEO ANCON Medical

Wesley Baker – CEO ANCON Medical

ANCON Team in Canterbury

“I’ve got cancer”. It’s the phrase that sends shivers down your spine. The one that happens to other people, not you.

The NBT device is very versatile. It can be used to screen for diseases such as cancer and later be reassigned to test for a range of other diseases when needed”

— Wesley Baker – CEO of ANCON Medical

BLOOMINGTON, MINNESOTA, USA, November 13, 2018 /EINPresswire.com/ — “I’ve got cancer”. It’s the phrase that sends shivers down your spine. The one that happens to other people, not you. Those 3 words that you pray you’ll never hear… or say. But when your loved one sits you down and plants it in front of you – so many questions jump to the foreground: What sort? How did you know? What can we do about it? And most provocatively – if we knew earlier, would it be a different story?

Lung cancer can grow silently, and predominantly the diagnosis comes after cancer has already spread. Most of the time when patients start having symptoms, like chest pain, weight loss or coughing up blood; the cancer is already in late stages. In the United States, lung cancer is the second most common cancer in both men and women but is the leading cause of cancer death. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.

75% of people diagnosed at stage 1 will survive lung cancer. By stage 4, this drops to 5% of people. Unfortunately, at present only 14.5% of patients are diagnosed at stage 1, showing there is an urgent and growing need to improve early diagnosis of this life-changing disease.

Lung cancer is precisely the kind of disease where ANCON Medical advanced disease screening technology can be life-saving. With further funding for the Nanoparticle Biomarker Tagging (NBT) technology, medical providers will be able to screen for cancers, as well as a range of other diseases, simply by testing a patient’s breath. The results can alert doctors to the presence of cancer and the need for further diagnosis, leading to life-saving treatment that can stop cancer before it can progress.

The technology works by detecting breath specific “biomarkers,” which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases. Researchers have discovered biomarkers for more than 400 diseases, including lung and other cancers.

By using machine learning software in association with the NBT technology the device can hunt for these specific molecules, so that the disease can be diagnosed early, thereby increasing treatment options and survival probability. No technology on the market is as highly sensitive at detecting biomarkers as NBT, which can detect the fingerprints of the disease at concentrations as low as one ion in 10,000 cubic centimeters, giving the device a sensitivity that could be measured down to a single molecule.

“The NBT device is very versatile. It can be used to screen for diseases such as cancer and later be reassigned to test for a range of other diseases when needed,” says ANCON Medical’s CEO, Wesley Baker, who is a member of the Royal Society of Medicine. “Lung cancer, scleroderma, cervical cancer, the Flu virus, tuberculosis and chronic obstructive pulmonary disease (COPD) are just some of the diseases where known biomarkers have been discovered, and ANCON’s NBT can improve the speed of diagnosis.”

Further reading:
For more information on Ancon Medical’s NBT technology research, visit http://anconmedical.com/nbt-technology/.
For UK statistics on Lung Cancer, visit www.cancerresearchuk.org.
For more information on the American Cancer Society, visit https://www.cancer.org/cancer/lung-cancer.html.

Joanna Stephens
Ancon Medical
+44 1227 811705
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

GETTING TRAPPED IN AN ADDICTION IS NO LONGER A ONE WAY TICKET.

Brain education is about actualizing your full emotional health power.

Wisdom education is brain cleaning education.

Wisdom Education is Brain Health Education; Where Wisdom Land is a Start...

Our Education System Has Cutting Edge Mind Education While Brain Education Is Under The Radar Screen.

Actualize Your Wisdom Power.

You Can Become Wise Now.

The problem is that addictions are a disease mainly of the brain and the experts try to educate the mind when it is the brain that needs healing.

ADDICTION IS THE ABNORAMMLY EXCESSIVE LOVE OF THE BAD HABIT THAT CAUSES TEMPORARY PLEASURE AND THEN RESTLESSNESS, UNEASE, TIREDNESS ETC. AND ONLY WHEN ONE LEARNS TO HATE IT WILL ONE BECOME FREE OF IT!”

— Sajid Khan

WASHINGTON, DC, USA, November 13, 2018 /EINPresswire.com/ — From amongst the 1% richest people to top leaders along with quite a large percentage of the population suffer from addiction in some form or another. Neither money nor power can help them to get rid of their affliction. There is a simple reason for this! Our experts have still not figured out how to cure this disease. The problem is that our experts have not figured out that the brain and mind are two separate entities. We lump them together as the single entity of the mind. When the brain is defective we still diagnose it as the mind that is defective. The experts have just one solution for any kind of bad habit. They try to educate the mind to try to give up this desire to indulge in the affliction. The problem is that this is a disease mainly of the brain. So the experts try to educate the mind when it is the brain that needs healing.

There is the brain wheel of consciousness and the mind wheel of consciousness. We keep focusing on the mind and keep educating it and educating it through better and better researched education. As a result the physical sciences keep improving and we are able to improve every industry. The net result is that the economy keeps lifting up. However emotional science is stagnant as its domain the brain is neglected and even miseducated. Thus finances keep improving but the emotions remain as unstable as ever. The first step towards solving these ills of society is to define clearly the brain and mind.

In the case of getting rid of addictions we must understand the following.

1) Mind:

The mind is the 'I'/self/me. The face of the mind is the self-image. The mind is the self-image.
To define the mind, define it as the self-image. To understand one's own mind understand one's own self-image. To heal the mind, heal the self-image.

2) Brain:

The brain is an organ of the body similar to the hands. Just like the mind/I is in full control of the hands the mind should be in full control of the brain. Ask yourself, are you the master of your brain or does your brain control parts of your self/mind?

When a person is addicted to sex or drugs or smoking or even one's own ego etc., it is the brain that is addicted along with the mind. The question is how to get the two off this disease.

The way things stand our culture is loaded with allurements and attractions to the extent that long before one has the first experience of the bad habit the desire takes root in the mind and the brain starts to fantasize about it. Many become receptive to the bad habit even before they have the first taste of it, then they taste it and like it so much that first the mind and then the brain both become addicted. As the addiction increases the brain starts to ooze toxic biochemicals. Especially in the case of sex addiction where approximately 9% of humanity gets trapped into, the person is fantasizing about sex but the brain is ready to 'jump' with the biochemicals pumped up and the person ready to go, all the time. This constant release of biochemicals tires the brain, the body, and the mind. Excess of any chemicals is bad and in this case over excess by far makes life miserable. It shows on the face. One can tell by the sweat as it becomes greasy. In extreme cases and there are many leaders who are afflicted to the extent that the desire for sex right now is turned on and never gets switched off. They are ready to jump again and again! It is like one is thirsty and drinks water again and again but the thirst is never quenched.

Here is how to overcome this disease.

You are your mind and no matter how deep the mind and brain are afflicted you have to take control of your mind. First you have to distinguish between your brain and your mind. The part of you that wants to be free of this habit is your mind and you will have to identify yourself with it.

Instead of thinking good about your addiction you have to hate it. Only when the mind begins to hate the bad habit will the brain first ease up on generating the toxic biochemicals and eventually the brain will give up generating the wrong desire. The solution is to experience and feel when the desire arises, not the pleasure of indulging in the bad habit but the tiredness, pain, embarrassment, restlessness, and unease, that the brain is producing. Whenever the thirst enters the mind take your mind off it and feel all the physical pain this addiction is causing. With your mind observe the release of these toxic biochemicals as they travel through the body. By observing, experiencing and feeling the pain instead of pleasure you will be able to stop the generation of the toxic biochemicals that are ravaging your mind, brain and body.

IT IS THE ABNORAMMLY EXCESSIVE LOVE OF THE BAD HABIT THAT CAUSES THE ADDICTION AND ONLY WHEN ONE LEARNS TO HATE IT WILL ONE BECOME FREE OF IT!

You can also contact us if you want your addiction free life back.

Sajid Khan, President
4th R Foundation
+1 201-450-8098
email us here

All emotions, including wisdom and love etc can now be defined in numbers. The art of living is now a science. Wisdom is a science!


Source: EIN Presswire

Parallel Trade for Pharma: Addressing Competition law and FMD challenges Registration is now open

Highly Anticipated Agenda Released for Europe's Only Parallel Trade Conference | 5 – 6 February 2019

LONDON, UNITED KINGDOM, November 13, 2018 /EINPresswire.com/ — SMi Group is proud to announce the return of Europe’s only Parallel Trade event conference, returning to Central London on 5th & 6th February 2019. The meeting will gather 90+ senior leaders in parallel trade to discuss upcoming trends and share best practices.

The 2019 event will hold a particular place of significance due to Brexit and the UK officially leaving the EU on the 29th of March 2019. As such, the UK will no longer be part of the EU free market; hence, having a significant impact on parallel trade.

Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2019. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.

The 2019 Parallel Trade conference will cover the important issues of:
• Patient safety
• Brexit’s impact on parallel trade
• The falsified medicines directive
• The supply chain and shortages
• The legal aspects of parallel trade within IP, anti-trust and competition law

This conference will enable you to update on parallel trade regulations to ensure compliance, recap on regional markets' parallel trade activities and outlooks and reassess and benchmark your supply chain and distribution model against peers for best practice.

2019 industry experts include:

o Miranda Cole, Partner, Covington & Burling
o Nerea Blanque, Senior Global Market Access & Pricing Manager, Almirall
o Felipe Florez-Arango, CFO, Allergan
o John Lisman, Attorney Consultant, Trainer, Lisman Legal Life Sciences B.V.
o Shabnam Hanassab, Engagement Manager, IQVIA
o Farasat A.S. Bokhari, Senior Lecturer, University of East Anglia
o Flemming Wagner, CEO, Covington & Burling
o Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceuticals Companies
o Antonio Mendonca Alves, CEO, MD Pharma
o Vimal Unewal, Senior Manager in Market Supply, Ferring Pharmaceuticals
o Mike Isles, Executive Director, European Alliance for Access to Safe Medicines
o Iona McCall, Senior Vice President, AlixPartners
o Martin Slegl, Regional Principal of East Europe, IQVIA
o Maarten Van Baelen, Market Access Director, Medicines for Europe
o Christopher Stothers, Partner, Freshfields Bruckhaus Deringer

Parallel Trade 2019 will also be accompanied by two exclusive post- conference workshops, running on 4th February 2019:
A: Parallel Trade & Brexit. What to expect?
Led by Key Pharmaceuticals Ltd

B: Understanding IP, regulatory & competition law issues in pharmaceuticals parallel trade
Led by Arnold & Porter LLP

For more information about the must-attend meeting please visit:
www.parallel-trade.com/einpr1

For those interested in registering, there is currently a £200 early bird discount available for all registrations made before 30th November 2018.

For media enquiries please contact Jinna Sidhu on +44 20 7827 6088 or email hsidhu@smi-online.co.uk

13th Annual Parallel Trade
5th – 6th February 2019
Holiday Inn Kensington Forum, London, UK

#smiparalleltrade

—- ENDS —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+1 2078276088
email us here


Source: EIN Presswire

Hear Vital Updates on Delivery Mechanisms of RNA-Based Drugs at the 10th Annual RNA Therapeutics Conference

RNA Therapeutics 2019

RNA Therapeutics 2019

SMi Reports: SMi’s RNA Therapeutics Conference 2019 is returning to London on the 20th & 21st February for its 10th year running.

LONDON, LONDON, UNITED KINGDOM, November 13, 2018 /EINPresswire.com/ — Despite the impressive strides recently being made in the field of RNA therapeutics, researchers still face major challenges for utilising them in a therapeutic context, including issues in intracellular delivery, stability, and immune response activation.

This year's two-day conference will provide a dedicated focus on these issues, in particular the challenges, as well as recent developments in delivery mechanisms.

Attendees will have the exclusive opportunity to hear the impressive experience and expertise of senior industry experts in the field discussing the various issues and potential solutions to mechanisms of delivery of RNA therapeutics, including:

Henrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
• Development of Formulations for Delivery of RNA and Small Molecules

Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
• Advances in Targeted Delivery of Anti-Sense Oligonucleotide Therapeutics to Pancreatic SS-Cells for Regenerative Approaches in Type 2 Diabetes

Ekkehard Leberer, Senior Director, Sanofi-Aventis Deutschland GmbH
• Delivering Therapeutic Oligonucleotides across Biobarriers: Opportunities and Challenges in Drug Development

Marian Gindy, Executive Director, MSD
• Advances in mRNA Delivery Technologies for Vaccines

In addition to a jam-packed agenda of insightful presentations and case studies, the conference will provide attendees with unique networking opportunities.

With a host of big pharmas, academics, pioneering biotechs, and government organisations, this year's highly-anticipated event will feature top representation from within the RNA Therapeutics field. Visit http://www.therapeutics-rna.com/einpr to register and take advantage of the £200 early-bird saving, valid until 30th November.

10th Annual RNA Therapeutics Conference
20th – 21st February 2019
London, UK

—END—

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
+442078276124
email us here


Source: EIN Presswire

Biologics Shown Effective for HIV+ Psoriasis Patients

SKIN-The Journal of Cutaneous Medicine® Article: A Review of Biologics and Other Treatment Modalities in HIV-Associated Psoriasis

A continually growing number of case reports reveals an important role for [biologics] in treating HIV-associated psoriasis without significant detriment to patients’ immune status.”

— Joshua Kaminetsky, BA

NEW YORK, NY, UNITED STATES, November 13, 2018 /EINPresswire.com/ — Psoriasis is a chronic skin condition that presents itself as red plaques. HIV is a sexually transmitted disease that lowers a person’s immune system. Patient with both psoriasis and HIV can be even more difficult to treat. For moderate to severe psoriasis, the most commonly used medications are biologics: injections that influence the immune system. Patients with HIV cannot afford to have their weakened immune system brought down further. One can understand why doctors face a unique challenge in treating patients with both of these conditions.

However, in a new article authored by Kaminetsky et al. the authors review the evidence to support the use of biologic medications for psoriasis in patients with coexisting HIV. The authors write “a continually growing number of case reports reveals an important role for [biologics] in treating HIV-associated psoriasis without significant detriment to patients’ immune status.”

Kaminetsky et al. discuss reports of patients with HIV and psoriasis who have been treated with Humira (adalimumab), Enbrel (etanercept), Remicaide (infliximab), and Stelara (ustekinumab). The authors do contend, however, that further studies are necessary, including robust clinical trials. They close with the following message: “the success of biologics has been encouraging, [but] due to the theoretical immunosuppressive risks, current recommendations favor their use only for cases that are unresponsive to other therapies.”

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details please visit www.jofskin.org or contact jofskin@gmail.com.

Link to article

(DOI: 10.25251/skin.2.6.6)

Joshua Kaminetsky
Icahn School of Medicine at Mount Sinai
+1 212-659-9530
email us here


Source: EIN Presswire

Polypodium Leucotomos Extract – An Oral Sunprotective Supplement – Found to Be Safe & Effective

SKIN-The Journal of Cutaneous Medicine® Article: Clinical Efficacy & Safety of Oral Polypodium Leucotomos Extract for Photoprotection: A Systematic Review

Most studies reported beneficial photoprotective effects of polypodium leucotomos extract as evidenced by increased minimal erythemal dose.”

— Giselle Prado, MD

NEW YORK, NY, UNITED STATES, November 13, 2018 /EINPresswire.com/ — Polypodium leucotomos extract is naturally obtained from a fern native to South America. It has been shown to have anti-oxidant and photoprotective properties when taken orally. The extract is not a sunscreen but can be one extra layer to a full sun protection package. A recent article reviewed all human studies published to date showing the clinical efficacy and safety of polypodium leucotomos extract.

Prado et al. wrote “Eighteen studies were found to meet [our] inclusion criteria. Most studies reported beneficial photoprotective effects of polypodium leucotomos extract as evidenced by increased minimal erythemal dose.” The concept of minimal erythemal dose has been used for decades in order to measure the efficacy of sunscreens. By increasing the minimal erythemal dose, a person would need more exposure to sun in order to burn.

In this study, the most popular formulation of the extract was Heliocare, made by Ferndale Healthcare. The authors go on to state “the extraction methodology of an herbal supplement can affects its potency and effects in humans. Without testing each specific formulation in humans, it can be difficult to compare different products that claim to have the same ingredients.” Therefore, consumers should be careful when purchasing their oral supplement of choice.

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details please visit www.jofskin.org or contact jofskin@gmail.com.

Link to article

(DOI: 10.25251/skin.2.6.2)

Giselle Prado
National Society for Cutaneous Medicine
+1 646-341-6468
email us here


Source: EIN Presswire

Psoriasis Risk Linked to Obesity; Weight Loss Shown to Improve Symptoms

SKIN-The Journal of Cutaneous Medicine® Article: Psoriasis and Obesity: A Review of the Current Literature

Because of the numerous detrimental effects of obesity on psoriasis, management should include weight loss as a foremost goal. ”

— Joshua Kaminetsky, BA

NEW YORK, NY, UNITED STATES, November 13, 2018 /EINPresswire.com/ — Psoriasis is a common skin condition that affects 2-3% of the world population. On the skin, psoriasis looks like red raised plaques with a dandruff like scale on top. Psoriasis doesn’t just affect the skin; it can cause psychological harm to patients due to low self esteem.

Several studies have shown that psoriasis is more common in obese patients. A recent article published in SKIN: The Journal of Cutaneous Medicine thoroughly reviews the relationship between psoriasis and obesity by analyzing many different studies and data sources. The article, authored by Orloff et al, states “Because of the numerous detrimental effects of obesity on psoriasis, management should include weight loss as a foremost goal. Weight reduction strategies have a well-documented beneficial effect.”

Understanding the effect of obesity on psoriasis is doubly important for patients because it can affect the dosing of their medications. Obese patients require more medication in order to treat their psoriasis. The review goes on to propose that “evidence suggests that weight loss also potentiates the efficacy of commonly used psoriasis medications.” Weight loss can make those stubborn psoriasis plaques easier to treat.

The authors close by suggesting that patients with psoriasis should discuss a well-rounded treatment plan with their dermatologists. This could include a combination of psoriasis medication and lifestyle changes that lead to weight loss.

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details please visit www.jofskin.org or contact jofskin@gmail.com.

Link to article

(DOI: 10.25251/skin.2.6.4)

Joshua Kaminetsky
Icahn School of Medicine at Mount Sinai
+1 212-659-9530
email us here


Source: EIN Presswire

Prefabricated Construction Fills The Gap Of Unskilled Labor

Modular Solutions factory

a better way to build

Accelerating Schedules

Modular Solutions are filling the gap where there is a shortage of skilled trade crews available

PHOENIX, AZ, UNITED STATES, November 12, 2018 /EINPresswire.com/ — Ask any contractor what they are currently struggling with, and the answer will be skilled trades. With the current economy many contractors are struggling to keep a good core team of workers available. Many workers are job hopping for a few cents an hour more and then the training process begins again.

Modular Solutions, Ltd of Phoenix, Arizona has a great solution for this challenge. Factory built structures are built off-site and then transported to site. This method of construction has been available for many years, but did not see the surge in construction growth until this recent labor shortage.

With traditional construction a skilled laborer is often traveling from job site to job site losing valuable family time due to long travel and hours on the road. When a building is constructed "off-site" the crew report to the same location (the factory) each day and the factory is able to keep a more loyal crew of dedicated construction teams.

Another benefit is that if building materials are shipped to a traditional construction site they are subject to theft, vandalism, or incorrect material order. This can slow the crews down and a project can be delayed by weeks, especially if the building material was a long lead order item. With prefabricated factory built construction the entire building package is ordered with the approved plans, and purchasing and receiving are able to control the material handling. This results in minimal time loss (if any) due to material shortages or mishandling.

Prefabricated construction is generally regulated by a state agency, and then approved by that agency via factory inspections or third party company inspections. The international building code (IBC) what agencies use to review design plans for a modular or traditional built structure. Both types of construction must comply with all aspects of the IBC building code. The unique aspect of factory built structures is that most factories have standard "approved" structural packages for the construction of the modular facility saving weeks of design time on a custom design-build project.

Modular Solutions, Ltd General Manager Brandon Hart is a second generation factory manager. According to Mr. Hart "There is no other solution like this where a customer can get a custom project in such a short time frame". The largest benefit to prefabricated construction is the accelerated construction schedule. Mr. Hart said "We service clients from all industries healthcare, multi-family, education, retail, developers, industrial, and more".

To learn more about prefabricated and modular construction contact Modular Solutions, Ltd preconstruction team.

Mitzi Garcia
Modular Solutions, Ltd
602-952-9741
email us here
Visit us on social media:
Facebook
Google+
LinkedIn

Modular Solutions for every industry


Source: EIN Presswire

AI microscopy for everyone

The restoration DL model receives as input a low signal to noise ratio (SNR) image (left) and output a high SNR image (right). Image depicts a cell with fluorescently labelled mitochondria imaged by iSIM (super resolution microscopy).

The segmentation DL model creates a confidence map (middle image) from an electron micrograph (left image). In the confidence map, white = cell, black = cell membrane. Image shows a mouse retina sample imaged by serial block face scanning electron microscopy.

The prediction DL model receives as input a bright field / phase contrast image of cells (left) and the model can predict and paint in the location and texture of each cell’s nucleus (center = predicted nuclei only, right = overlay of raw image and predicted nuclei).

DRVISION announces the launch of Aivia Cloud, the pioneering, universally usable artificial intelligence platform for scientific imaging applications.

BELLEVUE, WA, USA, November 12, 2018 /EINPresswire.com/ — DRVISION announces the launch of Aivia Cloud, the pioneering, universally usable artificial intelligence (AI) platform for scientific imaging applications. The unique cloud-desktop hybrid platform for training and deployment of deep learning (DL) models is the result of an 18 month long joint industry-academy R&D project which involved 25 experts in AI, life sciences, microscopy and image analysis.

DL, a type of AI technology, is revolutionizing many areas of our daily lives and is now starting to be adopted by the life sciences imaging community. In the past 18 months, a growing volume of DL-based scientific reports have shown that DL-powered tools can help solve microscopy and image analysis problems. DL-powered tools can be used to improve image resolution, to increase image signal to noise ratio, automatically identify objects of interest, and predict the localization of subcellular features in microscopy images (reference 1-4). These approaches allow scientists to run previously impossible imaging experiments and quickly extract meaning from raw data. Aivia Cloud users can directly apply any of the three DRVISION-trained models (see images for examples), train new DL models exclusively with their own data or choose to augment one of the pre-trained models by transfer learning. Aivia Cloud leverages Google Cloud Platform’s state-of-the-art computing infrastructure, as well as TensorFlow, Keras and Python.

"AI has the potential to redefine the limits of microscopy which would greatly accelerate the rate of knowledge creation. However, due to the massive shortage of deep learning experts the wider imaging community has not been able to benefit from this type of tech. In collaboration with our academic partners, our in-house experts have created a pipeline that can be used by any scientist, no coding or AI experience needed. Aivia Cloud is set to democratize the use of AI for a myriad of image-based applications for both life and material sciences" says Luciano Lucas (PhD), Executive VP at DRVISION.

What are the factors limiting the adoption of DL technology for life sciences imaging applications:
DL-based technology is currently only used by small group of pioneering research groups. This is due to four major practical hurdles: (1) the requirement for multiple highly specialized and disjointed software libraries or tools to cover the entire DL train-apply workflow. This step often requires users to reformat or resave their data in several different file formats; (2) the need to have extensive expertise to finetune the training process; (3) the need to access expensive, high-performance hardware to train DL networks, and (4) the difficulty and time-consuming properties of ground truth (GT) creation.

Aivia Cloud removes the first three bottlenecks and accelerates the generation of GT data. The first issue is resolved by creating a fully integrated platform which covers the whole pipeline, from the creation of ground truth annotations to training and applying DL models. The second issue is addressed by developing and testing hyperparameter optimization procedures (patent pending) which are robust for the three application types initially supported. The third issue is solved by integrating and leveraging a world class cloud computing platform – the Google Cloud Platform. The final issue is solved by Aivia’s patented machine learning technology, parameter-free image segmentation as well as Aivia’s non-ML high performance image processing tools.

Aivia Cloud was publicly launched in San Diego, California, USA, at the world’s largest neuroscience conference: the annual meeting of the Society for Neuroscience (SfN) that brings together over 30K attendees. For more information and to request early access to Aivia Cloud, contact Luciano Lucas (lucianol@drvtechnologies.com, +1 425 773 1548).

Presentation introducing Aivia Cloud (and Aivia 8): https://youtu.be/VP9QlRfrdZA

More information:
Aivia Cloud: www.drvtechnologies.com/aivia-cloud
Aivia 8 (also launched): https://www.drvtechnologies.com/aivia8
Aivia (overview of all functionality): https://www.drvtechnologies.com/aivia
Deep Learning in Aivia: https://www.drvtechnologies.com/deep-learning-aivia

About DRVISION Technologies:
DRVISION works with scientists and engineers at the technological frontier, and pioneers image based decision technologies that propel major breakthroughs in the life science, electronics and materials industries. DRVISION is a technological innovator with 50 issued US patents, and commercial interests in X-ray inspection, survey, search / alignment, video inspection and life sciences. DRVISION makes and markets Aivia microscopy image analysis software. Aivia development is partially funded by the National Institutes of Health (NIH) under multiple Small Business Innovative Research (SBIR) programs worth over $10M. For more information, visit www.drvtechnologies.com.

Image credits
Restoration and prediction DL model example: Dr. Hari Shroff, Dr. Jiji Chen, Mr. Yijun Su (NIBIB/NIH, Bethesda, USA)
Electron microscopy segmentation DL model example: Prof. Rachel Wong and Dr. Wan-Qing Yu (University of Washington, Seattle, USA).

References
1. Riverson Y, et al., Optica, Volume 4, Issue 11, (2017)
2. Weigert M, et al., Biorxiv, (2018)
3. Turaga SC, et al., Neural Computation, Volume 22, Issue 2, (2010)
4. Christiansen EM, et al., Cell, Volume 173, Issue 3, (2018)

Luciano Lucas
DRVISION Technologies
+1 425-773-1548
email us here


Source: EIN Presswire